MRK ▲ +2.8% - Merck & Co., Inc.
$MRK - Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026
10-OCT-2026 06:19 PM ET
Share this post
More filings for $MRK
MRK ▲ +0.3% - Merck & Co., Inc.Sep 30, 2026MRK ▲ +0.3% - Merck & Co., Inc.Sep 30, 2026MRK ▲ +0.1% - Merck & Co., Inc.Sep 28, 2026MRK ▲ +0.4% - Merck & Co., Inc.Sep 25, 2026MRK ▲ +0.4% - Merck & Co., Inc.Sep 25, 2026MRK ▲ +0.2% - Merck & Co., Inc.Sep 22, 2026
View full $MRK filing history →💬 Comments
Loading comments…
Leave a comment